Gelteq Limited (GELS)

CIK 0001920092 · Healthcare · Drug Manufacturers

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
—
Document and Entity Information
—
Audit Information
—
Statements
Consolidated Statement of Profit Or Loss and Other Comprehensive Income
—
Consolidated Statement of Financial Position
—
Consolidated Statement of Changes In Equity
—
Consolidated Statement of Cash Flows
—
Notes
Basis of Preparation
—
Borrowings
—
Capital Commitments
—
Capital Commitments Property, Plant and Equipment
—
Cash and Cash Equivalents
—
Changes In Liabilities Arising From Financing Activities
—
Contingent Assets & Liabilities and Commitments
—
Corporate Expenses
—
Critical Accounting Judgements, Estimates and Assumptions
—
Cybersecurity Risk Management and Strategy Disclosure
—
Deferred Revenue
—
Depreciation and Amortisation Expense
—
Dividends
—
Employee Benefits Provisions
—
Employment Expenses
—
Events After The Reporting Period
—
Finance Costs
—
Financial Risk Management
—
General Information
—
Guarantees
—
Income Tax Expense
—
Insider Trading Policies and Procedures
—
Intangible Assets
—
Interests In Subsidiaries
—
Inventories
—
Ipo Related Expenses
—
Issued Capital
—
Key Management Personnel
—
Lease Commitments
—
Lease Liabilities
—
Loss Per Share
—
Operating Segments
—
Other Income
—
Prepayments and Other Assets
—
Reconciliation of Loss Before Income Tax To Net Cash Used In Operating Activities
—
Related Party Transactions
—
Remuneration of Auditors
—
Research Expenses
—
Revenue From Contracts With Customers
—
Right-of-use Assets
—
Share-based Payments
—
Summary of Significant Accounting Policies
—
Trade and Other Payables
—
Trade and Other Receivables
—